Research Analysts Issue Forecasts for LAB Q1 Earnings

Standard BioTools Inc. (NASDAQ:LAB) – Analysts at KeyCorp issued their Q1 2025 earnings per share (EPS) estimates for Standard BioTools in a research note issued to investors on Wednesday, February 26th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.06) per share for the quarter. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Standard BioTools’ current full-year earnings is ($0.29) per share.

Standard BioTools Price Performance

LAB opened at $1.06 on Monday. Standard BioTools has a fifty-two week low of $0.99 and a fifty-two week high of $3.04. The company’s 50-day moving average is $1.58 and its 200 day moving average is $1.79. The firm has a market capitalization of $394.59 million, a P/E ratio of -1.49 and a beta of 1.57.

Insider Activity at Standard BioTools

In other Standard BioTools news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The stock was bought at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the purchase, the director now owns 58,846,780 shares of the company’s stock, valued at approximately $62,377,586.80. This represents a 8.92 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 53.10% of the stock is owned by company insiders.

Institutional Trading of Standard BioTools

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Standard BioTools by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 6,975,221 shares of the company’s stock valued at $12,209,000 after purchasing an additional 25,504 shares during the last quarter. Hollow Brook Wealth Management LLC purchased a new stake in shares of Standard BioTools in the third quarter worth $10,679,000. State Street Corp grew its holdings in shares of Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after buying an additional 1,157,984 shares during the last quarter. Barclays PLC lifted its holdings in shares of Standard BioTools by 13.2% during the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after purchasing an additional 377,195 shares in the last quarter. Finally, Mirabella Financial Services LLP purchased a new stake in shares of Standard BioTools during the 4th quarter valued at about $5,478,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.